Patent ID: 11857520
Assignee: NORTIC HOLDINGS INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 14:
15. A method of treating pain associated with a condition selected from the group consisting of tri-geminal neuralgia, facial neuropathic pain, facial cancer induced neuropathic pain, migraine pain, and cluster headache pain, comprising
incorporating a preservative-free nasal spray formulation into a mechanical multi-dose nasal spray pump device, the nasal spray formulation consisting of from about 5% to about 30% w/v of a locally acting sodium channel blocker selected from the group consisting of lidocaine, mepivacaine, bupivacaine, ropivacaine, chloroprocaine, procaine, tetracaine, a pharmaceutically acceptable salt thereof, and any combination of the foregoing to treat pain, from about 0.25% to about 5% w/v of a buffering agent, the buffering agent being in a sufficient amount to provide a pH of the nasal spray formulation from about pH 4.5 to about pH 7, an optional second active agent selected from the group consisting of epinephrine, ketamine, a vasodilator, an anticonvulsant drug, a muscle relaxant, and combinations of any of the foregoing, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration, the nasal spray formulation having a viscosity from about 0.8 to about 1.1 cps, and
intranasally administering the nasal spray formulation by actuating the mechanical multi-dose nasal spray pump device and spraying 1-2 sprays in each nostril of a human subject, for a total of 4 sprays in every application, the mechanical multi-dose nasal spray pump device spraying a unit dose of the nasal spray formulation in a wide plume such that the spray pump pattern has a mean spray angle from about 60 to about 90 degrees, and droplet size when actuated such that the mean Dv10 is from about 10 to about 30 μm, the mean Dv50 is from about 20 to about 60 μm, and the mean Dv90 is from about 80 to about 120 μm, the unit dose when sprayed into the nasal cavity of a human patient being therapeutically effective to treat a condition selected from the group consisting of tri-geminal neuralgia, facial neuropathic pain, facial cancer induced neuropathic pain, migraine pain, and cluster headache pain, wherein the mechanical multi-dose nasal spray pump device when actuated provides a volume of about 0.04 ml to about 0.2 ml.